GeneCentric Therapeutics Appoints Brian Kelly as SVP Business Development

DURHAM, N.C.--(BUSINESS WIRE)--#GeneCentric--GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced the appointment of Brian Kelly as Senior Vice President of Business Development. Mr. Kelly will be responsible for spearheading the Company’s global business growth strategy, with a focus on diagnostic partnering and biopharmaceutical alliance programs and other corporate development initiatives to advance the Company’s strategic priorities.

A business leader in cancer research and genomic analysis technologies, Mr. Kelly has more than 15 years’ experience in global business and market development, companion diagnostics and biomarker strategies. Prior to joining GeneCentric, he most recently served as Vice President, Global Biopharma and Companion Diagnostics Strategy at Caris Life Sciences and Global Director, Diagnostic Partnering at Thermo Fisher Scientific. Prior to that, he held various clinical market development and commercial roles at Life Technologies, Pacific Biosciences and Affymetrix. Prior to his time in industry, he held research positions at Johns Hopkins University School of Medicine, where he focused on biomarker discovery in oncology.

"Brian is the perfect addition to our team as a scientific business leader who will help us leverage our proprietary technology, IP and gene expression tests to expand our diagnostic and biopharmaceutical partnerships," said Michael Milburn, PhD, President and CEO at GeneCentric. “Having already established strategic collaborations with Labcorp, Tempus and leading biopharmaceutical companies, GeneCentric is at a pivotal growth stage. We look to Brian’s experience to further develop those relationships and cultivate new partnerships.”

“I am excited to join the talented GeneCentric team to help further the development and adoption of advanced diagnostics. Given the growing clinical adoption of next-generation sequencing of transcriptomes, the time has arrived to enable the use of advanced multi-gene signatures to better explain complex cancer biology and expand the use of precision medicines,” said Brian Kelly, Senior Vice President at GeneCentric. “Establishing truly strategic partnerships with both biopharma and diagnostics thought-leaders is key to creating the evidence and access to support both physicians and patients.”

Mr. Kelly holds a bachelor’s degree in biology from Towson University and a master’s degree in biology with a bioinformatics concentration from Johns Hopkins University.

About GeneCentric

GeneCentric Therapeutics, Inc. is an RNA-based genomic solutions provider based in Durham, North Carolina. The company designed its technologies to parse the complexity of tumor and immune biology using its RNA-based Tumor and Immune Micro-Environment (rT(I)ME) Explorer platform to discover and develop signatures of responder populations to oncology therapeutics. GeneCentric commercializes its technology through strategic collaborations with pharmaceutical, biotechnology and diagnostics companies in applications throughout preclinical testing, clinical drug development and commercialization lifecycle phases. For more information, visit www.genecentric.com or follow us on LinkedIn.

Robin Fastenau
Robin.Fastenau@GeneCentric.com